HHS Secretary Kennedy Announces Potential Peptide Reclassification (February 2026)

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced the administration’s intent to reclassify more than 14 peptides from Category 2 (restricted) back to Category 1 (can be compounded), reversing the FDA’s 2023-2024 restrictions.

The Announcement

Kennedy framed the reclassification as part of a broader health freedom initiative, arguing that the original Category 2 designations had cut off patient access to compounds with legitimate therapeutic use. The announcement was made via public statement and generated significant attention in the peptide and integrative medicine communities.

Peptides Targeted for Reclassification

The following 14+ peptides were identified for potential Category 2 to Category 1 reclassification:

1. BPC-157 — tissue repair and gut healing
2. TB-500 (Thymosin Beta-4) — wound healing
3. CJC-1295 — growth hormone releasing hormone analog
4. Ipamorelin — growth hormone secretagogue
5. AOD-9604 — anti-obesity peptide
6. GHRP-2 — growth hormone releasing peptide
7. GHRP-6 — growth hormone releasing peptide
8. Melanotan II — melanocortin peptide
9. GHK-Cu — copper peptide for skin and tissue repair
10. Epithalon — telomerase activator
11. Selank — anxiolytic peptide
12. Semax — nootropic peptide
13. KPV — anti-inflammatory tripeptide
14. PT-141 (Bremelanotide) — sexual dysfunction peptide

Additional peptides may be included in the final reclassification.

Implementation Status (as of April 2026)

Formal implementation is still in progress. Key considerations:

• The FDA must go through a rulemaking or guidance process to formally change Category designations
• There is bureaucratic resistance within the FDA, which originally made the Category 2 designations
• Legal challenges from pharmaceutical companies are possible, particularly for peptides that compete with approved drugs
• The timeline for formal implementation remains unclear
• Some compounding pharmacies have begun preparing to resume peptide compounding in anticipation

Implications

For Compounding Pharmacies

• Would restore a significant revenue stream lost in 2023-2024
• Pharmacies need to re-establish peptide sourcing and quality testing infrastructure
• 503A pharmacies would need valid prescriptions; 503B outsourcing facilities could compound without patient-specific prescriptions

For Patients

• Legal access to compounded peptides through licensed pharmacies would resume
• Quality assurance would improve vs. grey-market sourcing
• Insurance coverage remains unlikely — these would still be compounded, not FDA-approved

For Grey-Market Vendors

• Legal compounding access would reduce demand for research-grade peptides
• Vendors like Peptide Sciences had already begun shutting down
• The market may consolidate around licensed pharmacies

For the Pharmaceutical Industry

• Companies developing peptide drugs (e.g., Novo Nordisk with semaglutide) may oppose reclassification
• Compounded peptides at lower prices compete with branded products
• Lobbying efforts expected to intensify

Context

This announcement came against the backdrop of:

• The original Category 2 designations that restricted these peptides
• Multiple grey-market vendor shutdowns in early 2026
• Growing public frustration with peptide access restrictions
• Kennedy’s broader agenda to reform FDA regulatory processes

Related Notes

• FDA-503A-Category-System — the category framework
• FDA-Category-2-Designations-2023-2024 — original restrictions
• FDA-Warning-Letters-April-2026 — continued enforcement despite pending reclassification